Teladoc Health (NYSE:TDOC) Price Target Cut to $5.50 by Analysts at Leerink Partners

Teladoc Health (NYSE:TDOC) had its target price dropped by Leerink Partners from $8.50 to $5.50 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “market perform” rating on the health services provider’s stock. Leerink Partners’ price objective indicates a potential upside of 1.76% from the company’s previous close.

Other equities research analysts have also issued reports about the stock. Barclays initiated coverage on shares of Teladoc Health in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 target price on the stock. Zacks Research lowered Teladoc Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. TD Cowen reduced their target price on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a report on Thursday. BMO Capital Markets reduced their price target on Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a research note on Thursday. Finally, Citigroup dropped their price target on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Friday, January 9th. Four investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $7.93.

Teladoc Health Price Performance

Shares of TDOC stock traded up $0.76 during trading hours on Thursday, hitting $5.41. 18,495,312 shares of the company’s stock were exchanged, compared to its average volume of 6,881,845. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $10.02. The stock has a market cap of $959.23 million, a price-to-earnings ratio of -4.21 and a beta of 2.12. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. The stock’s 50-day moving average is $6.06 and its 200-day moving average is $7.22.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. The business had revenue of $642.27 million for the quarter, compared to the consensus estimate of $635.33 million. During the same quarter in the prior year, the company earned ($0.28) EPS. The firm’s quarterly revenue was up .3% on a year-over-year basis. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. As a group, research analysts forecast that Teladoc Health will post -1.16 EPS for the current year.

Insiders Place Their Bets

In other news, insider Carlos Nueno sold 3,897 shares of Teladoc Health stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total value of $29,188.53. Following the transaction, the insider owned 27,175 shares in the company, valued at approximately $203,540.75. This trade represents a 12.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the sale, the chief executive officer owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. This represents a 7.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 33,288 shares of company stock worth $251,684. 0.58% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Jupiter Asset Management Ltd. boosted its holdings in Teladoc Health by 293.9% in the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after acquiring an additional 2,880,008 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Teladoc Health by 23.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock worth $53,260,000 after purchasing an additional 1,325,106 shares during the period. Trexquant Investment LP bought a new stake in shares of Teladoc Health in the 4th quarter valued at $9,156,000. Monaco Asset Management SAM increased its position in shares of Teladoc Health by 159.2% during the fourth quarter. Monaco Asset Management SAM now owns 1,956,947 shares of the health services provider’s stock worth $13,699,000 after buying an additional 1,201,947 shares during the period. Finally, Allianz Asset Management GmbH raised its stake in Teladoc Health by 189.2% during the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock worth $12,518,000 after buying an additional 1,059,458 shares during the last quarter. Institutional investors own 76.82% of the company’s stock.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 results topped expectations: Teladoc posted a narrower-than-expected GAAP loss (EPS -$0.14 vs. -$0.19 consensus) and revenue of $642.3M slightly above estimates, driven by international and Integrated Care strength which helped offset BetterHelp weakness. Teladoc Tops Q4 Earnings
• Positive Sentiment: Bank of America upgraded TDOC from Neutral to Buy and set a $7 price target, signaling conviction from a large shop and providing buy-side momentum. BofA Upgrade
• Positive Sentiment: Piper Sandler reaffirmed an Overweight rating with a $9 price target (albeit reduced from $12), underscoring that some sell-side analysts still see meaningful upside based on recovery potential. Piper Sandler Note
• Neutral Sentiment: Company provided forward revenue range for 2026 ($2.47B–$2.59B) and emphasized investments in AI, insurance partnerships, and international expansion — strategic positives, but longer‑term and already partly baked into expectations. 2026 Revenue Projection
• Neutral Sentiment: Investors can review the full earnings call transcript and slide deck for detail on segment trends and cost actions; useful for modeling but not immediate catalysts by themselves. Earnings Call Transcript Slide Deck
• Negative Sentiment: Guidance was weaker than Street expectations: Q1 EPS guide (-$0.45 to -$0.35 vs. est -$0.28) and Q1 revenue guide ($598M–$620M vs. est ~$633M) came in below consensus, and FY EPS range (-$1.10 to -$0.70) is wider/poorer than modeled — a primary reason for intra‑day pressure before buyers stepped in. Earnings & Guidance
• Negative Sentiment: Several firms trimmed price targets and lowered ratings (Cowen to $6 Hold, BMO to $5 Market Perform, Wells Fargo to $6 Equal Weight, Stifel to $6 Hold), signaling more cautious near‑term views from parts of the sell side and creating downward pressure despite the beat. Analyst PT Cuts BMO Note

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.